Fate Therapeutics Inc. (FATE): What is the Risk Factor?


Fate Therapeutics Inc. (NASDAQ:FATE) saw a downside of -2.16% to close Tuesday at $5.43 after subtracting -$0.12 on the day. The 5-day average trading volume is 3,109,240 shares of the company’s common stock. It has gained $5.91 in the past week and touched a new high 1 time within the past 5 days. An average of 6,571,120 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,643,928.

FATE’s 1-month performance is -55.67% or -$5.58 on its low of $4.02 reached on 01/06/23. The company’s shares have touched a 52-week low of $4.02 and high of $43.14, with the stock’s rally to the 52-week high happening on 01/05/23. YTD, FATE has lost -46.18% or -$4.66 and has reached a new high 3 times. However, the current price is down -87.41% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

FATE stock investors last saw insider trading activity on Jan 13.Valamehr Bahram (Chief R&D Officer) most recently sold 10,917 shares at $5.24 per share on Jan 10. This transaction cost the insider $57,205. President and CEO, Wolchko J Scott, sold 45,907 shares at a price of $5.24 on Jan 10. Then, on Jan 10, Chief Technical Officer Plavsic Mark sold 3,418 shares at a price of $5.24 per share. This transaction amounted to $17,910.

Valuation Metrics

FATE stock has a beta of 1.57. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.90 while the price-to-book (PB) in the most recent quarter is 1.02.

Fate Therapeutics Inc.’s quick ratio for the period ended September 29 was 5.20, with the current ratio over the same period at 5.20. The firm’s gross profit as reported stood at $272.84 million against revenue of $55.85 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 48.17% to -$83.56 million, while revenue of -$76.11 million was 8.92% off the previous quarter. Analysts expected FATE to announce -$0.89 per share in earnings in its latest quarter, but it posted -$0.86, representing a 3.40% surprise. EBITDA for the quarter stood at more than -$82.82 million. FATE stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 231.35 million, with total debt at $110.92 million. Shareholders hold equity totaling $97.17 million.

Let’s look briefly at Fate Therapeutics Inc. (FATE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 26.89% to suggest the stock is trending oversold, with historical volatility in this time period at 509.07%.

The stock’s 5-day moving average is $5.58, reflecting a -5.07% or -$0.29 change from its current price. FATE is currently trading -53.43% above its 20-day SMA, -79.10% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -71.09% and SMA200 by-86.67%.

Stochastic %K and %D was 19.72% and 20.77% and the average true range (ATR) pointed at 0.76. The RSI (14) points at 25.65%, while the 14-day stochastic is at 19.00% with the period’s ATR at 0.92. The stock’s 9-day MACD Oscillator is pointing at -0.14 and -0.78 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Fate Therapeutics Inc. (NASDAQ: FATE), H.C. Wainwright downgraded it to a Neutral rating. They previously had a Buy rating on the stock.


Please enter your comment!
Please enter your name here